Q2 2020 EPS Estimates for BRAINSWAY LTD/S (NASDAQ:BWAY) Lifted by Oppenheimer

BRAINSWAY LTD/S (NASDAQ:BWAY) – Equities researchers at Oppenheimer raised their Q2 2020 EPS estimates for shares of BRAINSWAY LTD/S in a research report issued to clients and investors on Wednesday, June 24th. Oppenheimer analyst S. Lichtman now anticipates that the company will post earnings of ($0.11) per share for the quarter, up from their previous estimate of ($0.17). Oppenheimer currently has a “Buy” rating and a $13.00 target price on the stock. Oppenheimer also issued estimates for BRAINSWAY LTD/S’s Q3 2020 earnings at ($0.08) EPS, Q4 2020 earnings at ($0.01) EPS and FY2020 earnings at ($0.34) EPS.

A number of other equities analysts also recently weighed in on BWAY. Cantor Fitzgerald cut their target price on BRAINSWAY LTD/S from $17.00 to $13.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 24th. Zacks Investment Research lowered shares of BRAINSWAY LTD/S from a “buy” rating to a “hold” rating in a research report on Thursday, June 25th. Raymond James cut their target price on shares of BRAINSWAY LTD/S from $13.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, March 24th. Finally, ValuEngine upgraded shares of BRAINSWAY LTD/S from a “hold” rating to a “buy” rating in a research report on Friday, March 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. BRAINSWAY LTD/S currently has a consensus rating of “Buy” and an average target price of $10.69.

Shares of NASDAQ BWAY opened at $5.92 on Monday. BRAINSWAY LTD/S has a twelve month low of $5.10 and a twelve month high of $12.53. The stock’s 50 day moving average price is $7.31 and its 200-day moving average price is $8.99. The company has a market capitalization of $65.57 million, a PE ratio of -10.96 and a beta of 0.91.

BRAINSWAY LTD/S (NASDAQ:BWAY) last announced its earnings results on Wednesday, June 24th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.15). BRAINSWAY LTD/S had a negative return on equity of 45.01% and a negative net margin of 53.74%. The business had revenue of $4.16 million during the quarter, compared to analysts’ expectations of $4.00 million.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Phoenix Holdings Ltd. boosted its position in BRAINSWAY LTD/S by 3.8% during the first quarter. Phoenix Holdings Ltd. now owns 321,895 shares of the company’s stock valued at $2,496,000 after buying an additional 11,895 shares during the period. Cowen AND Company LLC purchased a new stake in BRAINSWAY LTD/S during the first quarter valued at about $2,734,000. Finally, Raymond James & Associates boosted its position in BRAINSWAY LTD/S by 54.1% during the fourth quarter. Raymond James & Associates now owns 28,500 shares of the company’s stock valued at $278,000 after buying an additional 10,000 shares during the period. Institutional investors and hedge funds own 17.37% of the company’s stock.

BRAINSWAY LTD/S Company Profile

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Read More: Dividend Yield

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.